Analystreport

Mirati Therapeutics, Inc. (NASDAQ: MRTX) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock.

Mirati Therapeutics, Inc.  (MRTX) 
Last mirati therapeutics, inc. earnings: 2/25 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.mirati.com/node/5806